Summary by Moomoo AI
On April 1, 2024, TC BioPharm (Holdings) PLC, a clinical-stage biotechnology company, announced the execution of a non-binding letter of intent (LOI) with an unnamed cell therapy company for the potential acquisition of several assets. These assets include a Solid Tumor tool kit, a NK Cell Manufacturing tool kit, and two CAR-NK programs. The terms of the acquisition involve a combination of cash, equity at closing, and milestone payments based on clinical achievements. The LOI indicates mutual interest and the final terms are subject to due diligence, definitive agreements, and various contingencies such as securing adequate financing and receiving necessary approvals. The completion of the transaction is uncertain, and there is no guarantee that it will proceed as contemplated...Show More